Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Equity Average (2016 - 2025)

Historic Equity Average for Theravance Biopharma (TBPH) over the last 12 years, with Q3 2025 value amounting to $228.8 million.

  • Theravance Biopharma's Equity Average rose 2061.09% to $228.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $228.8 million, marking a year-over-year increase of 2061.09%. This contributed to the annual value of $194.3 million for FY2024, which is 4066.23% down from last year.
  • Theravance Biopharma's Equity Average amounted to $228.8 million in Q3 2025, which was up 2061.09% from $195.4 million recorded in Q2 2025.
  • Theravance Biopharma's Equity Average's 5-year high stood at $461.2 million during Q4 2022, with a 5-year trough of -$350.6 million in Q2 2022.
  • In the last 5 years, Theravance Biopharma's Equity Average had a median value of $189.7 million in 2024 and averaged $58.4 million.
  • Per our database at Business Quant, Theravance Biopharma's Equity Average plummeted by 8696.76% in 2021 and then surged by 30245.85% in 2023.
  • Over the past 5 years, Theravance Biopharma's Equity Average (Quarter) stood at -$331.1 million in 2021, then skyrocketed by 239.3% to $461.2 million in 2022, then crashed by 50.22% to $229.6 million in 2023, then decreased by 21.33% to $180.6 million in 2024, then grew by 26.67% to $228.8 million in 2025.
  • Its Equity Average stands at $228.8 million for Q3 2025, versus $195.4 million for Q2 2025 and $170.8 million for Q1 2025.